A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease.

Trial Profile

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE-PD
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 28 Apr 2017 Results of a post-hoc subgroup analysis evaluating the efficacy of extended-release carbidopa-levodopa in advanced Parkinson's disease patients with or without concomitant medication use, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of a post-hoc analysis assessing the effect of "OFF" time on the recommended starting dose of extended-release carbidopa-levodopa capsules, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of post hoc analysis assessing number of "off" episodes as well as the number and duration of "on" episodes, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top